Market Overview

UPDATE: Deutsche Bank Reiterates Buy Rating, Lowers PT on Gilead Sciences

Share:
Related GILD
Gilead, Bank Of America, Costco: Fast Money Picks For September 28
15 Biggest Mid-Day Losers For Tuesday
Valeant: Is Bankruptcy Possible? (Seeking Alpha)

In a report published Wednesday, Deutsche Bank reiterated its Buy rating on Gilead Sciences (NASDAQ: GILD), but lowered its price target from $95.00 to $48.00.

Deutsche Bank noted, “We are updating our TP and EPS estimates for Gilead's recent 2:1 stock split. Our new TP is $48 & our pre-split TP was $95. Our new 4Q12, FY 2012 and 2013 non-GAAP EPS estimates are $.51, $1.98, and $2.35 respectively. New 4Q12 fully diluted share count is 1582 with average share count of 1568 for FY 2012. We have made no changes to our revenue projections or expenses. Our thesis remains unchanged on HCV & HIV.”

Gilead Sciences closed on Tuesday at $39.90.

Latest Ratings for GILD

DateFirmActionFromTo
Sep 2016Leerink SwannDowngradesOutperformMarket Perform
Sep 2016BerenbergInitiates Coverage onBuy
Sep 2016Credit SuisseMaintainsOutperform

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings

 

Related Articles (GILD)

View Comments and Join the Discussion!